文献速递神经外周血管技术与安全PETCT

多放射性示踪剂PET/CT评估颈动脉粥样硬化斑块易损性的范围综述

Assessment of carotid atherosclerotic plaque vulnerability with multi-radiotracer PET/CT: a scoping review.
PubMed 文献 · Eur Radiol · 2025-11-28

本范围综述纳入2010至2024年37项使用18F-FDG、18F-NaF、18F-FMISO、68Ga-DOTATATE、68Ga-Pentixafor和11C-乙酸酯的PET研究,评估多放射性示踪剂PET/CT识别易损颈动脉粥样硬化斑块的证据。多示踪剂PET/CT可能提供新的诊断见解,但采集参数和分析方法异质性大,缺乏标准方案,需标准化成像参数和组织学验证。

要点

  • 多放射性示踪剂PET/CT在检测易损颈动脉斑块方面显示出应用潜力。
  • PET/CT采集参数(摄取时间、示踪剂剂量)和分析方法存在显著变异,无统一标准。
  • 协议异质性影响可重复性,需标准化成像参数和组织学验证以推动临床使用。

核心结论

  • 多放射性示踪剂PET/CT可能为颈动脉粥样硬化斑块诊断提供新见解并改善易损斑块识别,但协议异质性影响可重复性,需标准化成像参数和组织学验证以推动未来临床应用。

研究设计与样本

  • 范围综述,检索2010至2024年发表的同行评议原创PET研究,使用Covidence平台筛选文献和提取数据,最终纳入37项研究。

关键影像表现/征象

  • 37项研究中7项(19%)采用系列双示踪剂PET/CT,包括18F-FDG/18F-NaF、18F-FDG/18F-FMISO、18F-FDG/68Ga-DOTATATE和18F-FDG/68Ga-Pentixafor。
  • 其余研究使用PET/CT 18F-FDG(N=26,70%)、18F-NaF(N=2,5%)、11C-乙酸酯(N=1,3%)和68Ga-DOTATATE(N=1,3%)。
  • PET/CT采集参数如摄取时间(分钟)[18F-FDG:50-180,18F-NaF:60-180,68Ga-DOTATATE:60-120]、示踪剂剂量(MBq)[18F-FDG:185-555,18F-NaF:125-370]和分析方法(靶本比和/或标准化摄取值)存在显著变异。

临床应用与阅片要点

  • 作者认为多示踪剂PET/CT可能为检测易损颈动脉斑块提供新的诊断见解,可能改善风险评估并识别脑血管事件高风险患者。
  • 作者指出需标准化成像参数和组织学验证以实现PET在颈动脉粥样硬化疾病评估中的未来临床应用。

局限性

  • PET/CT采集参数如摄取时间[18F-FDG:50-180分钟,18F-NaF:60-180分钟,68Ga-DOTATATE:60-120分钟]、示踪剂剂量[18F-FDG:185-555 MBq,18F-NaF:125-370 MBq]和分析方法(靶本比和/或标准化摄取值)存在显著变异。
  • 尚无明确共识界定使用PET/CT评估颈动脉斑块的标准方法。
  • 协议异质性影响可重复性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Atherosclerotic carotid artery disease (CarAD) is a significant contributor to the global burden of cerebrovascular diseases. Several positron emission tomography computed tomography (PET/CT) radiotracers showed promising results in identifying and assessing vulnerable carotid atherosclerotic plaque. This review aims to assess the current evidence surrounding the use and potential of multiple PET radiotracers in identifying vulnerable carotid atherosclerotic plaque.

MATERIALS AND METHODS: A scoping review of the literature was conducted for original peer-reviewed articles of PET studies published between 2010 and 2024 that used 18F-fluorodeoxyglucose (18F-FDG), 18F-sodium fluoride (18F-NaF), 18F-fluoromisonidazole (18F-FMISO), 68Ga-DOTATATE, 68Ga-Pentixafor, and 11C-Acetate for the evaluation of vulnerable carotid atherosclerotic plaque. The Covidence platform facilitated the screening of articles and data extraction.

RESULTS: 37 studies matched the inclusion criteria. Seven (19%) included serial dual-tracer PET/CT with 18F-FDG/18F-NaF, 18F-FDG/18F-FMISO, 18F-FDG/68Ga-DOTATATE, and 18F-FDG/68Ga-Pentixafor. The remaining studies used PET/CT 18F-FDG (N = 26, 70%), 18F-NaF (N = 2, 5%), 11C-Acetate (N = 1, 3%) and 68Ga-DOTATATE (N = 1, 3%). Substantial variation in PET/CT acquisition parameters such as uptake time (min) [18F-FDG: 50-180, 18F-NaF: 60-180, and 68Ga-DOTATATE: 60-120], radiotracer dose (MBq) [18F-FDG: 185-555, 18F-NaF: 125-370] and analysis methods [target-to-background ratio and/or standardised uptake values] were observed with no clear consensus on what constitutes a standard approach for carotid plaque evaluation using PET/CT.

CONCLUSION: The use of multiple PET radiotracers may provide novel diagnostic insights into the diagnosis of CarAD and improve the identification of vulnerable carotid atherosclerotic plaque. However, protocol heterogeneity affects reproducibility, necessitating standardised imaging parameters and histological validation to enable future clinical use of PET for CarAD assessment.

KEY POINTS: Question Conventional atherosclerotic plaque assessments, focusing on vessel occlusion, lack predictive power for vulnerable carotid atherosclerotic plaque. Can multi-radiotracer PET/CT, targeting plaque metabolic processes, address this? Findings Multi-radiotracer PET/CT demonstrates promising potential in detecting vulnerable carotid atherosclerotic plaque, but variability in data acquisition and analysis methods persists. Clinical relevance This review shows that multi-radiotracer PET/CT may provide novel diagnostic insights for detecting vulnerable carotid atherosclerotic plaque, potentially enhancing risk assessment and identifying patients at higher risk of cerebrovascular events.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Readford TR, Kench PL, Ugander M, et al. Assessment of carotid atherosclerotic plaque vulnerability with multi-radiotracer PET/CT: a scoping review. Eur Radiol. 2025. PMID: 41310133. doi:10.1007/s00330-025-12186-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。